2015 American Transplant Congress
Everolimus Versus Mycophenolate for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin and Tacrolimus
Introduction: Recipients of kidneys recovered from expanded criteria donors are at higher risk to develop delayed graft function (DGF) and acute rejection (AR), leading to…2015 American Transplant Congress
CMV-Specific CD154+T-Cells and CMV Disease Status After Liver Or Intestine Transplantation (LTx, ITx)
Background: Preliminary data suggest that measuring host cellular immunity using CMV-specific IFNg+T-cells can potentially enhance decision making about discontinuation of antiviral therapy and secondary prophylaxis…2015 American Transplant Congress
Myeloid Cells as a Key Mediator for Impairment of Transplant Tolerance by CMV Infection
Cytomegalovirus (CMV) is a ubiquitous virus that presents a significant risk for reactivation or de novo infection in transplant recipients. Clinical transplant tolerance has recently…2015 American Transplant Congress
A Primary Cytomegalovirus Infection Post-Transplantation Has a Significant Impact on Circulating T Cells and Renal Allograft Function
Study's purpose: Cytomegalovirus (CMV)-infection may profoundly affect the peripheral T-cell compartment and is associated with T-cell ageing and generation of cytotoxic CD4+CD28null T cells. We…2015 American Transplant Congress
Virus Induced CD28 Down-Regulation as a Potential Driver of Costimulation Blockade Resistant Rejection
1Surgery, Emory University, Atlanta, GA; 2Surgery, Duke University, Durham, NC.
Belatacept, a B7-specific fusion protein, blocks CD28-B7 costimulation and prevents kidney allograft rejection. However, it is ineffective in a sizable minority of patients. Although T…2015 American Transplant Congress
Human CMV-Specific CD8 T Cells Exhibit Distinct Phenotypes and Distribution Patterns in Tissues and Circulation
IntroductionCMV persists and is controlled by T cells in multiple tissues; however, study of CMV responses has largely been limited to blood containing only 2-3%…2015 American Transplant Congress
Analysis of In-Vitro Effects of Immunosuppression on NK Cell Subsets in the Presence of Cytomegalovirus
Background: NK cells may play an important role in the control of CMV replication post-transplant. NK cells can be divided into subsets based on surface…2015 American Transplant Congress
CMV IgG Provides Similar Anti-CMV Efficacy as Valganciclovir in High-Risk Organ Transplant Recipients, With Reduced Costs
Abdominal organ transplants at high risk for CMV infection (D+/R-) remain a difficult cohort to prevent late CMV infection despite prolonged valganciclovir (VGC) administration. Administration…2015 American Transplant Congress
Incidence of CMV Viremia in Obese and Morbidly Obese Kidney Transplants Under a Low Dose Valganciclovir Prophylaxis Protocol
1Pharmacy Practice, Univ of IL-Chicago, Chicago, IL; 2Surgery, Univ of IL-Chicago, Chicago, IL.
Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to…2015 American Transplant Congress
Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis
Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal…
American Transplant Congress abstracts